New Onset of Erectile Dysfunction in a Cohort of Patients Enrolled in Active Surveillance for Low Risk Prostate Cancer

After serum Prostate Specific Antigen (PSA) concentration was introduced as a screening test in prostate disease, prostate cancer has been increasingly detected at an early stage and grade. PSA test leads to Prostate Cancer (PCa) over diagnosis and overtreatment.

To overcome overtreatment, low risk PCa patients are enrolled in AS in order to prevent overtreatment, delaying curative treatment according to neoplasm progression.

The AS protocols were approved to delay radical treatment and spare treatment; however AS can influence quality of life related to health defined as “a physical, mental, and social well-being and not merely the absence of disease.

PDF LINK